Clinical Trials · NCT06148649
Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Dongguan HEC Biopharmaceutical R&D Co., Ltd.
- Enrollment
- 234
- Start date
- Dec 2023
- Locations
- 2 sites, China
- Primary endpoint
- Change from baseline of HbA1c at week 12